Additional Research Activities. For the avoidance of doubt, the main focus of the collaboration shall be the activities defined in the initial Research Programme, however, during the Extended Research Term the Research Programme may be amended upon BOEHRINGER’s request, for certain Targets to be mutually agreed between the Parties in accordance with Section 3 of the Agreement, e.g., but not limited to, regarding research activities with regard to additional non-GPCR targets of enzymes or ion channels.
Additional Research Activities. (a) In the event that prior to the end of the Research Term, all research activities directed to [*****] Research [*****] and Research [*****] have been successfully completed or terminated by agreement of the Parties, then DOW shall have the right to propose to DIVERSA:
(i) [*****] Research [*****] or Research [*****] to be pursued in the Areas of Interest under the R&D Program, or
(ii) deploying the FTEs on Research [*****] and Research [*****] which are already underway, or
(iii) if (i) and (ii) are not available, then considering deploying, using their good faith efforts, the FTE's on Research [*****] or Research [*****] within the Areas of Interest and for which DIVERSA has [*****] or serious obligations ([*****]) to a Third Party, or
(iv) if (i) through (iii) are not available, then reducing the number of FTE's and [*****] for those FTEs no longer required computed in accordance with Section 4.4. If DIVERSA does not have [*****] with respect to the Research [*****] or Research [*****] proposed in Section 2.1.4(a)(i) or (iii) and does not have a [*****] on its own behalf or with a Third Party, the Parties shall negotiate in good faith the terms on which such additional research activities may be conducted under the R&D Program. Such additional research activities will only be initiated if the Parties reach written agreement on the terms thereof, including, without limitation, milestone and other payments on resulting products.
(b) During the R&D Program DOW may also propose that additional research activities directed to [*****] and Research [*****] and Research [*****] within those Areas of Interest, using their good faith efforts, be conducted in connection with the R&D Program. In such event, the Parties shall discuss an expansion of the R&D Program, provided DIVERSA shall have no obligation to conduct any such activities with DOW unless terms for such activities are agreed to in writing by the Parties. If DIVERSA does not have a [*****] with respect to a proposed additional Research [*****]or Research [*****]on its [*****] or with a Third Party, DIVERSA will notify DOW in writing of such within [*****] days of the proposal, and within [*****] days of such notice, the RMC will implement a [*****] for each additional Research [*****] or Research [*****]. In the event the RMC fails to initiate a [*****] Plan within such [*****] day period, or if DOW notifies DIVERSA in writing that it does not intend to pursue an additional Research [*****] or Resear...
Additional Research Activities. (a) In the event that prior to the end of the Research Term, the parties agree that the FTEs involved in the R&D Program cannot be productively used to conduct research on the Trait Categories, then PIONEER shall have the right to propose to MAXYGEN additional research activities to be conducted in connection with the R&D Program in new trait categories. If MAXYGEN does not have prior obligations to a third party with respect to such research activities, or have a prior intention to conduct activities relating to the proposed activities on its own behalf or with a third party, it shall notify PIONEER, and in such case, the parties shall negotiate in good faith the terms on which such research activities could be conducted in connection with the R&D Program. Such research activities will only be initiated if the parties reach written agreement on the terms thereof, including without limitation, milestone payments and royalties on resulting products.
(b) If it appears that one or more research projects regarding the Shuffling of Genes in the Trait Categories will not be completed by the end of the Research Term and the RDSC agrees that such research projects are near completion, PIONEER may with notice to MAXYGEN at least sixty (60) days prior to the end of the Research Term extend the Research Term with respect to such research projects for a period of [*******], or such other period as PIONEER and MAXYGEN may agree in writing (the "Extension Period"). In any such event, PIONEER shall provide FTE funding for such projects during the Extension Period equal to the average level of FTE support provided in the R&D Program for such research projects in the six (6) month period prior to the [*******] anniversary of the Effective Date, such funding to be paid to MAXYGEN on the [*******] anniversary of the Effective Date.
Additional Research Activities. The JRC may require that certain activities under the Research Plans be repeated, new research be conducted, that Bi-Specific Constructs be created, modified or re-engineered or other research-related activities related to the Licensed Antibodies be performed and the JRC will adjust the applicable Research Plan and the associated budget accordingly. In each case, [**] shall be responsible for all Research Costs incurred under any such amended Research Plan budget that is approved by the JSC. During the Term, in connection with Development activities under any Program, Incyte may, in its discretion, select by written notice to Merus, one or more General Monoclonal Antibodies for potential use in the generation of a Bi-Specific Construct under such Program. Promptly after such notice, Merus will notify Incyte whether Merus has granted rights to such General Monoclonal Antibody to any Third Party. If Merus has granted rights to such General Monoclonal Antibody to a Third Party, Incyte may (but shall not be required to) request that Merus create a monoclonal Antibody that is less than [**] homologous in HCDR3 to such General Monoclonal Antibody and subsequently deem such modified General Monoclonal Antibody a Selected Monoclonal Antibody under such Program. Incyte may request that Merus generate Bi-Specific Constructs using such modified General Monoclonal Antibody (in which case, the provisions of Section 2.8(b) shall not be applicable to such modified General Monoclonal Antibody). If Merus has not granted rights to the General Monoclonal Antibody to any Third Party, Incyte may deem such General Monoclonal Antibody as a Selected Monoclonal Antibody under such Program. If Incyte wishes to designate one or more General Monoclonal Antibodies as Selected Monoclonal Antibodies under this Section 4.11, and the total number of Selected Monoclonal Antibodies would subsequently exceed the applicable number authorized by Section 1.127, Incyte shall contemporaneously designate an equal number of Selected Monoclonal Antibodies of its choice to become General Monoclonal Antibodies such that there will thereafter be only the number of Selected Monoclonal Antibodies authorized by Section 1.127 for such Program. If Incyte deems one or more General Monoclonal Antibodies as Selected Monoclonal Antibodies under this Section 4.11, and the total number of Selected Monoclonal Antibodies on either individual arm of a Target Pair would subsequently exceed [**], Incyte shall contempo...
Additional Research Activities. UCSF will perform the research activities described in the Research Project Scope of Work attached hereto as Exhibit A (the “Additional SOW”).
